Furthermore, the data obtained can serve as guidelines in further rational optimization and development of β-carbolines towards active compounds that would potentially be useful as MAO-A-specific inhibitors with therapeutic application in the treatment of depression. This evidence concerns the gene MAOA and major depressive disorder.